Cigna is a national commercial insurer with broadly typical PA practices for GLP-1 medications.

Type 2 diabetes coverage

Generally covered for T2D. Typical copay $25–$100/month with PA.

Weight management coverage

Variable. Cigna commercial plans cover Wegovy and Zepbound for weight indication with PA; some employer-elected plans exclude weight management.

Cardiovascular indication coverage

Coverage under March 2024 Wegovy CV indication expanding.

OSA indication coverage

Coverage of Zepbound for OSA expanding.

Prior authorization criteria (typical)

Typical PA criteria: BMI thresholds; documented lifestyle modification 3–6 months; comorbidity documentation.

If your plan excludes weight-management drugs

Verify with your specific plan; cash-pay compounded as alternative if PA fails.

How to verify

The most reliable way to verify coverage is to call the member services number on your insurance card and ask: (1) Is [Wegovy/Zepbound/Ozempic/Mounjaro] on my formulary? (2) What tier? (3) What are the prior authorization criteria? (4) What's my expected copay at each tier? Document the date, the rep's name, and any reference number.

Cash-pay alternative

If insurance coverage is unworkable, see our price index for current cash-pay compounded options. NexLife, our editorial pick, lists compounded semaglutide at $95–$109 and tirzepatide at $115–$129 a month depending on plan length (prices as of November 6, 2026); see the NexLife review.

See also

· Full insurance coverage guide · All carriers

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.